EP1218528A1 - Zellen, die retrovirale vektoren produzieren - Google Patents

Zellen, die retrovirale vektoren produzieren

Info

Publication number
EP1218528A1
EP1218528A1 EP00964529A EP00964529A EP1218528A1 EP 1218528 A1 EP1218528 A1 EP 1218528A1 EP 00964529 A EP00964529 A EP 00964529A EP 00964529 A EP00964529 A EP 00964529A EP 1218528 A1 EP1218528 A1 EP 1218528A1
Authority
EP
European Patent Office
Prior art keywords
ltr
vector
producer cell
noi
recombinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00964529A
Other languages
English (en)
French (fr)
Inventor
Jason Slingsby
Susan Mary Oxford BioMedica KINGSMAN (UK) Ltd.
Jonathan Oxford BioMedica ROHLL (UK) LTD.
Andrew Oxford BioMedica SLADE (UK) Ltd.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Publication of EP1218528A1 publication Critical patent/EP1218528A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Definitions

  • the present invention relates to retroviral vectors, in particular to high titre regulatable retroviral vectors.
  • Retroviruses have been proposed as a delivery system (otherwise expressed as a delivery vehicle or delivery vector) for inter alia the transfer of a nucleotide sequence of interest (NOI), or a plurality of NOIs, to one or more sites of interest. The transfer can occur in vitro, ex vivo, in vivo, or combinations thereof. When used in this fashion, the retroviruses are typically called retroviral vectors or recombinant retroviral vectors. Retroviral vectors have been exploited to study various aspects of the retrovirus life cycle, including receptor usage, reverse transcription and RNA packaging (reviewed by Miller, 1992 Curr Top Microbiol Immunol 158: 1-24).
  • At least part of one or more of the gag, pol and env protein coding regions may be removed from the virus. This makes the retroviral vector replication-defective. The removed portions may even be replaced by a NOI in order to generate a virus capable of integrating its genome into a host genome but wherein the modified viral genome is unable to propagate itself due to a lack of structural proteins. When integrated in the host genome, expression of the NOI occurs - resulting in, for example, a therapeutic effect.
  • the transfer of a NOI into a site of interest is typically achieved by: integrating the NOI into the recombinant viral vector; packaging the modified viral vector into a virion coat; and allowing transduction of a site of interest - such as a targetted cell or a targetted cell population.
  • retroviral vectors e.g. to prepare suitable titres of the retroviral vector
  • propagation and isolation may entail isolation of the retroviral gag, pol and env genes and their separate introduction into a host cell to produce a "packaging cell line".
  • the packaging cell line produces the proteins required for packaging retroviral RNA but it does not produce RNA-containing retroviral vectors.
  • the helper proteins can package the ⁇ z-positive recombinant vector to produce the recombinant virus stock. This can be used to infect cells to introduce the NOI into the genome of the cells.
  • the recombinant virus whose genome lacks all genes required to make viral proteins can infect only once and cannot propagate. Hence, the NOI is introduced into the host cell genome without the generation of potentially harmful retrovirus.
  • a summary of the available packaging lines is presented in "Retroviruses" (1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 449).
  • Retroviral packaging cell lines have been developed to produce retroviral vectors. These cell lines are designed to express three components, which may be located on three separate expression constructs.
  • the gag/pol expression construct encodes structural and enzymatic components required in particle formation, maturation, reverse transcription and integration.
  • the envelope (env) construct expresses a retroviral or non-retroviral envelope protein, which mediates viral entry into cells by binding to its cognate receptor.
  • the third expression construct produces the retroviral RNA genome containing a psi region, which is packaged into mature, enveloped retroviral particles.
  • the transfection of a plasmid DNA construct into packaging cells from a MLV packaging cell line of human origin, called FLYA13 yielded low retroviral vector titres even when different transfection reagents such as calcium phosphate precipitation and fugene transfection reagent were used.
  • the average titres from selected stably transfected cell lines clones ranged from about 10 3 to about 10 4 per ml.
  • clones generated by electroporation of constructs gave similar titres of from about 10° to about 10 4 per ml with no clones identified producing at >10 3 per ml.
  • retroviral transduction is a preferred method for genome introduction into packaging cell lines in order to generate high titre producer cell lines.
  • retroviral transduction is used to introduce a regulated/inactivated retroviral vector genome into packaging cell lines, the regulated retroviral vectors may not be produced in sufficient quantities from these cell lines.
  • some retroviral vectors may comprise (i) internal expression constructs which are themselves regulated or (ii) regulated elements which are present in retroviral 3' LTR sequences, either by design or by their nature.
  • these regulated vectors include but are not limited to hypoxic regulated vectors and self inactivating (SIN) vectors. If transduced producer cell lines are generated with these regulated vectors, the regulated or inactivated 3' U3 sequence of the LTR is copied to the 5' LTR by the process of retroviral reverse transcription and integration. Therefore, in the producer cell line, the 5' U3 promoter sequence directing expression of retroviral RNA genomes is identical to the regulated or inactivated 3' U3 promoter. This will result in very low levels of retroviral genome production and consequently low titres of functional retrovirus vectors being produced.
  • a regulated retroviral system includes MLV and lentivirus vector constructs where the 3' retroviral U3 enhancer element is replaced with a hypoxia responsive element (HRE) or other physiologically regulated, tumour specific or tissue- specific promoters.
  • HRE hypoxia responsive element
  • the 3' U3 sequence containing the HRE element is copied to the 5' LTR position and retroviral genomes will only be produced under hypoxic conditions or chemical mimics of hypoxia, such as heavy metal ions and desferrioxamine.
  • hypoxia responsive element such as heavy metal ions and desferrioxamine.
  • lentivector U3 enhancers are dependent on the transactivator TAT for transcriptional activation. Therefore, a lentivector producer cell line generated by transduction requires the presence of TAT for high level expression of the lentivector genome construct. The expression of TAT is not preferable in such a packaging cell line and therefore, in the absence of TAT, only very low titres will be produced from transduced producer cells generated in this way.
  • a regulated retroviral systems includes MLV or lentivirus self- inactivating (SIN) vectors. These vectors contain deletions of the elements in their 3' U3 sequences responsible for transcriptional activity. Therefore, on transduction of target cells, the transcriptionally inactive 3' U3 sequence is copied to the 5' LTR position. In standard configurations, an internal expression cassette directs therapeutic or marker gene expression. However, if SIN vectors are used to make a transduced retroviral producer line, there will be no transcriptional elements present to direct high levels of retroviral RNA genome expression.
  • the packaged viral vectors produced by transcription of the pro viral genome within the producer cells may then ultimately be used to transduce target cells where the regulatable sequences present in the 3 'LTR of the provirus in the producer cells are then present in the 5'LTR of the provirus in the target cells and consequently regulate transcription from the provirus as required.
  • the present invention allows transduced producer cells to be constructed that are capable of producing high titre regulated retroviral vectors by virtue of comprising a 5'LTR that directs high level expression of the viral genome in the producer cell and a different 3'LTR which as a result of the process of integration into a target cell will then result in a provirus in the target cell genome that exhibits regulatable expression.
  • the present invention allows the modification of a provirus integrated into the genome of the producer cells that have been selected for their high titre virus production such that the resulting packaged viral particles produced from the provirus may be used to transduce target cells resulting in a provirus integrated into the genome of the target cells that has a different, and preferably regulatable 5'LTR to that of the producer cell provirus.
  • the present invention is not limited to replacement of the 3'LTR of the provirus in the high titre producer cells, but may also include replacement of the 5'LTR and other viral sequences and/or the introduction of NOIs by the use of suitable constructs, as shown in the Figures.
  • the present invention provides a method of modifying a producer cell which producer cell comprises integrated into its genome a provirus which provirus comprises one or more recombinase recognition sequences within or upstream of its 3' LTR, the method comprising: introducing into the cell a construct comprising a 5' recombinase recognition sequence, an LTR and a 3' recombinase recognition sequence in that order, in the presence of a recombinase which is capable of acting on the recombinase recognition site(s) such that the nucleotide sequence between the 5' and 3' recombinase recognition sequences in the construct is introduced into the provirus.
  • the LTR is a heterologous regulatable LTR.
  • the present invention further provides a nucleic acid vector comprising a 5' recombinase recognition sequence, a regulatable LTR and a 3' recombinase recognition sequence in that order.
  • nucleic acid molecule and/or nucleic acid vector further comprises at least one NOI between the 5 ' recombinase recognition sequence and the regulatable LTR.
  • nucleic acid molecule and/or nucleic acid vector further comprises a 5'LTR and/or a packaging signal
  • the LTR is inactive/transcriptionally quiescent.
  • the construct, nucleic acid molecule and/or nucleic acid vector of the invention may be used in a recombinase assisted method to introduce a regulated LTR into a proviral genome integrated into a producer cell genome.
  • the present invention also provides a producer cell obtainable by the method of the invention, preferably a high titre producer cells. Also provided is an infectious retroviral particle obtained by the above method.
  • the present invention further provides ' a high titre producer cell comprising integrated into its genome a provirus, which provirus comprises a recombinase recognition site, a 5' LTR and a 3'LTR which 3'LTR differs from the 5'LTR.
  • a producer cell will typically have been produced by the method of the invention.
  • the 5'LTR and the 3'LTR referred to for the purposes of comparison are both “active".
  • active within the present context means transcriptionally active, that is to say, the 5'LTR comprises a promoter that directs transcription of the viral genome and the 3'LTR comprises a transcriptional stop sequence to terminate transcription. This distinction is relevant since if a provirus produced by the method of the invention comprises more than one 5' LTR or 3'LTR, at least one but not all must be active to allow viral production. Further, if the provirus comprises more than one 3'LTR then it is generally the upstream one that will be active since transcription will tend not to read through to the downstream 3 ' LTR.
  • the comparison should be performed between the additional 3'LTR and the original 5'LTR and not the two original LTRs.
  • it is permitted to have a 5'LTR and 3'LTR within the same provirus that are the same provided that there is also a 5'LTR and 3'LTR that differ.
  • the present invention provides a derived producer cell comprising integrated into its genome a retroviral vector comprising in the 5' to 3' direction a first 5' LTR; a second NOI operably linked to a second regulatable 3' LTR; and a third 3'LTR; wherein the third 3'LTR is positioned downstream of the second regulatable 3'LTR in the producer cell.
  • the first 5' LTR comprising 5'R and 5' U5 sequences is derivable from a first vector
  • the second NOI operably linked to a second regulatable 3' LTR is derivable from a second vector
  • the third 3'LTR is derivable from the first vector.
  • the first vector further comprises an internal LTR located upstream of the first NOI and downstream of the packaging signal wherein the Internal LTR comprises a heterologous U3 sequence linked to heterologous R and U5 sequences.
  • heterologous R and U5 sequences are lentiviral derivable R and U5 sequences, such as EIAV R and U5 sequences.
  • the third 3'LTR is transcriptionally active but expression is directed away from the second regulatable 3'LTR.
  • the second vector comprises a second NOI operably linked to a second regulatable 3'LTR comprising at least one recombinase recognition sequence.
  • the second regulatable 3'LTR comprises a deletion in the U3 sequences in the 3'LTR.
  • the second NOI comprises a discistronic construct, more preferably a discistronic construct comprising a therapeutic gene, an internal ribosomal entry site (IRES) and a reporter gene.
  • a discistronic construct comprising a therapeutic gene, an internal ribosomal entry site (IRES) and a reporter gene.
  • IRS internal ribosomal entry site
  • the present invention further provides in another embodiment, a method for producing a high titre regulatable retroviral vector, the method comprising the steps of:
  • a derived producer cell comprising integrated into its genome a first vector
  • introducing a second vector into the derived producer cell using a recombinase assisted method wherein the derived producer cell comprises a retroviral vector comprising in the 5' to 3' direction a first 5' LTR; a second NOI operably linked to a second regulatable 3' LTR; and a third 3'LTR; wherein the third 3'LTR is positioned downstream of the second regulatable 3'LTR in the derived producer cell.
  • the present invention also provides the use of a recombinase assisted mechanism to introduce a regulated 3'LTR into a derived producer cell line to produce a high titre regulated retroviral vector.
  • the high titre regulated retroviral vector particles of the present invention are typically generated in a suitable producer cell.
  • Producer cells are generally mammalian cells but can be, for example, insect cells.
  • a producer cell may be a packaging cell containing the virus structural genes, normally integrated into its genome into which the regulated retroviral vectors of the present invention are introduced.
  • the producer cell may be transfected with nucleic acid sequences encoding structural components, such as gag/pol/env on one or more vectors such as plasmids, adenovirus vectors, herpes viral vectors or any method known to deliver functional DNA into target cells.
  • the vectors according to the present invention are then introduced into the packaging cell by the methods of the present invention.
  • the term "producer cell” or “vector producing cell” refers to a cell which contains all the elements necessary for production of regulated retroviral vector particles and regulated retroviral delivery systems.
  • the producer cell is obtainable from a stable producer cell line.
  • the producer cell is obtainable from a derived stable producer cell line.
  • the producer cell is obtainable from a derived producer cell line
  • derived producer cell line is a transduced producer cell line which has been screened and selected for high expression of a marker gene. Such cell lines contain retroviral insertions in integration sites that support high level expression from the retroviral genome.
  • derived producer cell line is used interchangeably with the term “derived stable producer cell line” and the term “stable producer cell line
  • the derived producer cell line includes but is not limited to a retroviral and/or a lentiviral producer cell.
  • the derived producer cell line is an HIV or EIAV producer cell line, more preferably an EIAV producer cell line.
  • envelope protein sequences, and nucleocapsid sequences are all stably integrated in the producer and/or packaging cell.
  • one or more of these sequences could also exist in episomal form and gene expression could occur from the episome.
  • packaging cell refers to a cell which contains those elements necessary for production of infectious recombinant virus which are lacking in a recombinant viral vector.
  • packaging cells typically contain one or more expression cassettes which are capable of expressing viral structural proteins (such as gag, pol and env) but they do not contain a packaging signal.
  • packetaging signal which is refered to interchangeably as “packaging sequence” or “psi” is used in reference to the non-coding sequence required for encapsidation of retroviral RNA strands during viral particle formation.
  • Packaging cell lines suitable for use with the above-described vector constructs may be readily prepared (see also WO 92/05266), and utilised to create producer cell lines for the production of retroviral vector particles. As already mentioned, a summary of the available packaging lines is presented in "Retroviruses" (1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 449).
  • the packaging cell lines are useful for providing the gene products necessary to encapsidate and provide a membrane protein for a high titre regulated retrovirus vector and regulated nucleic gene delivery vehicle production.
  • regulated retrovirus sequences When regulated retrovirus sequences are introduced into the packaging cell lines, such sequences are encapsidated with the nucleocapsid (gag/pol) proteins and these units then bud through the cell membrane to become surrounded in cell membrane and to contain the envelope protein produced in the packaging cell line.
  • These infectious regulated retroviruses are useful as infectious units per se or as gene delivery vectors.
  • the packaging cell may be a cell cultured in vitro such as a tissue culture cell line.
  • Suitable cell lines include but are not limited to mammalian cells such as murine fibroblast derived cell lines or human cell lines.
  • the packaging cell line is a human cell line, such as for example: HEK293, 293-T, TE671, HT1080.
  • the packaging cell may be a cell derived from the individual to be treated such as a monocyte, macrophage, blood cell or fibroblast.
  • the cell may be isolated from an individual and the packaging and vector components administered ex vivo followed by re-administration of the autologous packaging cells.
  • the method of the present invention utilises a recombinase assisted mechanism.
  • the method of the present invention utilises a recombinase assisted mechanism which facilitates the production of high titre regulated retroviral vectors from the producer cells of the present invention.
  • recombinase assisted system includes but is not limited to a system using the Cre recombinase / loxP recognition sites of bacteriophage PI or the site- specific FLP recombinase of S. cerevisiae which catalyses recombination events between 34 bp FLP recognition targets (FRTs).
  • the site-specific FLP recombinase of S. cerevisiae which catalyses recombination events between 34 bp FLP recognition targets (FRTs) has been configured into DNA constructs in order to generate high level producer cell lines using recombinase-assisted recombination events (Karreman et al. (1996) NAR 24, 1616-1624).
  • FRTs FLP recognition targets
  • Vanin et al ibid suggests that his Cre-mediated recombination approach to retroviral producer cell line production may be used in combination with other modifications which should result in improved vector performance. Vanin et al ibid also suggests that his approach provides a means to generate high titre SIN vectors.
  • Vanin et al makes no reference to hypoxic regulated vectors and/or regulated/inactivated lentiviral vectors.
  • each retroviral genome comprises genes called gag, pol and env which code for virion proteins and enzymes.
  • these genes are flanked at both ends by regions called long terminal repeats (LTRs).
  • LTRs are responsible for proviral integration, and transcription. They also serve as enhancer-promoter sequences. In other words, the LTRs can control the expression of the viral gene.
  • Encapsidation of the retroviral RNAs occurs by virtue of a psi sequence located at the 5' end of the viral genome.
  • LTR long terminal repeat
  • the LTRs themselves are identical sequences that can be divided into three elements, which are called U3, R and U5.
  • U3 is derived from the sequence unique to the 3' end of the RNA.
  • R is derived from a sequence repeated at both ends of the RNA and
  • U5 is derived from the sequence unique to the 5' end of the RNA.
  • the sizes of the three elements can vary considerably among different retroviruses.
  • RNA and the DNA forms of the MLV retroviral genome is presented in Figure 7 in which the elementary features of the LTRs and the relative positioning of gaglpol and env are indicated. Please note that (i) gag pol and env are normally not spaced apart; and (ii) the overlap normally present between the pol and env genes and the poly A tail normally present at the 3' end of the RNA transcript are not illustrated in Figure 7.
  • the basic molecular organisation of an infectious retroviral RNA genome is (5') R - U5 - gaglpol, env - U3-R (3').
  • gag, pol and env may be absent or not functional.
  • the R regions at both ends of the RNA are repeated sequences.
  • U5 and U3 represent unique sequences at the 5' and 3' ends of the RNA genome respectively.
  • the viral DNA is translocated into the nucleus where the linear copy of the retroviral genome, called a preintegration complex (PIC), is randomly inserted into chromosomal DNA with the aid of the virion integrase to form a stable provirus.
  • PIC preintegration complex
  • the number of possible sites of integration into the host cellular genome is very large and very widely distributed.
  • the retroviral genome is introduced into packaging cell lines using retroviral transduction.
  • retroviral vector particles (such as MLV vector particles) are prepared in a transient expression system with a different envelope pseudotype to the packaging cell, and used to transduce a retroviral packaging cell.
  • the retroviral transduction step identifies retroviral insertions in integration sites that support high level expression of the resulting regulated retroviral genome.
  • Preferably stable transduced producer cell lines made by this initial retroviral transduction step produce retrovirus at titres of at least 10 6 per ml, such as from about 10 6 to about 10 7 per ml, more preferably at least about 10 7 per ml.
  • high titre means an effective amount of a retroviral vector or particle which is capable of transducing a target site such as a cell.
  • the term "effective amount” means an amount of a regulated retroviral or lentiviral vector or vector particle which is sufficient to induce expression of an NOI at a target site.
  • the titre is from at least 10 6 retrovirus particles per ml, such as from about 10 to about 10 7 per ml, more preferably at least about 10 7 retrovirus particles per ml.
  • the control of pro viral transcription remains largely with the noncoding sequences of the viral LTR.
  • the site of transcription initiation is at the boundary between U3 and R in the left hand side LTR (as shown in Figure 7) and the site of poly (A) addition (termination) is at the boundary between R and U5 in the right hand side LTR (as shown in Figure 7).
  • the 3'U3 sequence contains most of the transcriptional control elements of the provirus, which include the promoter and multiple enhancer sequences responsive to cellular and in some cases, viral transcriptional activator proteins.
  • AN LTR present for example, in the construct of the invention and as a 3'LTR in the provirus of the producer cell of the invention may be a native LTR or a heterologous regulatable LTR. It may also be a transcriptionally quiescent LTR for use in SIN vector technology.
  • the terms "regulatable LTR” and “regulatable 3'LTR” include vectors which contain responsive elements which are present in retroviral 3' LTR sequences, either by design or by their nature.
  • vectors comprising a “regulatable 3'LTR” are referred to as "regulated retroviral vectors”.
  • the 3'U3 sequence contains most of the transcriptional control elements of the provirus, which include the promoter and multiple enhancer sequences responsive to cellular and in some cases, viral transcriptional activator proteins.
  • Responsive elements include but are not limited to elements which comprise, for example, promoter and multiple enhancer sequences responsive to cellular and in some cases, viral transcriptional activator proteins and/or elements which have been modified to render them inactive.
  • modified includes but is not limited to silencing, disabling, mutating, deleting or removing all of the U3 sequence or a part thereof.
  • regulated LTR also includes an inactive LTR such that the resulting provirus in the target cell can not produce a packagable viral genome (self-inactivating (SIN) vector technology) - see the Examples and Figure 6 for a particular embodiment.
  • SINK self-inactivating
  • the term “enhancer” includes a DNA sequence which binds other protein components of the transcription initiation complex and thus facilitates the initiation of transcription directed by its associated promoter.
  • the enhancer is an ischaemic like response element (ILRE).
  • ILRE ischaemic like response element
  • ischaemia like response element otherwise written as ILRE - includes an element that is responsive to or is active under conditions of ischaemia or conditions that are like ischaemia or are caused by ischaemia.
  • conditions that are like ischaemia or are caused by ischaemia include hypoxia and/or low glucose concentration(s).
  • hypoxia means a condition under which a particular organ or tissue receives an inadequate supply of oxygen.
  • Ischaemia can be an insufficient supply of blood to a specific organ or tissue. A consequence of decreased blood supply is an inadequate supply of oxygen to the organ or tissue (hypoxia). Prolonged hypoxia may result in injury to the affected organ or tissue.
  • a preferred ILRE is an hypoxia response element (HRE).
  • hypoxia is a powerful regulator of gene expression in a wide range of different cell types and acts by the induction of the activity of hypoxia-inducible transcription factors such as hypoxia inducible factor- 1 (HIF-1 ; Wang & Semenza 1993 Proc Natl Acad Sci 90:430), which bind to cognate DNA recognition sites, the hypoxia-responsive elements (HREs) on various gene promoters.
  • HRE-1 hypoxia inducible factor-1
  • HREs hypoxia-responsive elements
  • HREEs Hypoxia response enhancer elements
  • HREEs have been isolated from regulatory regions of both the muscle glycolytic enzyme pyrivate kinase (PKM) gene (Takenaka et al 1989 J Biol Chem 264: 2363-2367), the human muscle-specific ⁇ -enolase gene (ENO3; Peshavaria and Day 1991 Biochem J 275: 427-433 ) and the endothelin-1 (ET-1) gene (Inoue et al 1989 J Biol Chem 264: 14954- 14959).
  • PLM muscle glycolytic enzyme pyrivate kinase
  • ENO3 human muscle-specific ⁇ -enolase gene
  • ET-1 endothelin-1
  • the HRE of the present invention is selected from, for example, the erythropoietin HRE element (HREE1), muscle pyruvate kinase (PKM), HRE element, phosphoglycerate kinase (PGK) HRE, B-enolase (enolase 3; ENO3) HRE element, endothelin-1 (ET-l)HRE element and metallothionein II (MTII) HRE element.
  • HREE1 erythropoietin HRE element
  • PLM muscle pyruvate kinase
  • HRE element phosphoglycerate kinase
  • PGK phosphoglycerate kinase
  • B-enolase enolase 3; ENO3
  • HRE element endothelin-1 (ET-l)HRE element
  • MMIII metallothionein II
  • the ILRE is used in combination with a transcriptional regulatory element , such as a promoter, which transcriptional regulatory element is preferably active in one or more selected cell type(s), preferably being only active in one cell type.
  • a transcriptional regulatory element such as a promoter, which transcriptional regulatory element is preferably active in one or more selected cell type(s), preferably being only active in one cell type.
  • this combination aspect of the present invention is called a responsive element.
  • the responsive element comprises at least the ILRE as herein defined.
  • Non-limiting examples ot such a responsive element are presented as OBHRE1 and
  • XiaMac Another non-limiting example includes the ILRE in use in conjunction with an
  • MLV promoter and/or a tissue rest ⁇ cted lschaemic responsive promoter are disclosed in W099/ 15684
  • tissue restricted promoters/enhancers are those which are highly active in tumour cells such as a promoter/enhancer trom a MUCl gene, a CEA gene or a 5T4 antigen gene
  • the alpha fetoprotein (AFP) promoter is also a tumour- specific promoter
  • One preferred promoter-enhancer combination is a human cytomegalovirus (hCMV) major immediate early (MIE) promoter/enhancer combination
  • promoter is used in the normal sense of the art, e g an RNA polymerase binding site
  • the promoter may be located in the retroviral 5' LTR to control the expresssion of a cDNA encoding an NOI
  • the NOI is capable of being expressed from the retrovirus genome such as from endogenous retroviral promoters in the long terminal repeat (LTR)
  • LTR long terminal repeat
  • the NOI is expressed from a heterologous promoter to which the heterologous g sene or sequence is operably linked
  • the promoter may be an internal promoter
  • NOI is expressed from an internal promoter
  • Vectors containing internal promoters have also been widely used to express multiple genes
  • An internal promoter makes it possible to exploit promoter/enhancer combinations other than those found in the viral LTR for driving gene expression
  • Multiple internal promoters can be included in a retroviral vector and it has proved possible to express at least three different cDNAs each from its own promoter (Overell et al 1988 Mol Cell Biol 8: 1803-1808).
  • Internal ribosomal entry site (IRES) elements have also been used to allow translation of multiple coding regions from either a single mRNA or from fusion proteins that can then be expressed from an open reading frame.
  • the promoter of the present invention may be constitutively efficient, or may be tissue or temporally restricted in their activity.
  • the promoter is a constitutive promoter such as CMV.
  • the promoters of the present invention are tissue specific.
  • tissue specific means a promoter which is not restricted in activity to a single tissue type but which nevertheless shows selectivity in that they may be active in one group of tissues and less active or silent in another group.
  • the level of expression of an NOI or NOIs under the control of a particular promoter may be modulated by manipulating the promoter region. For example, different domains within a promoter region may possess different gene regulatory activities. The roles of these different regions are typically assessed using vector constructs having different variants of the promoter with specific regions deleted (that is, deletion analysis). This approach may be used to identify, for example, the smallest region capable of conferring tissue specificity or the smallest region conferring hypoxia sensitivity.
  • tissue specific promoters may be particularly advantageous in practising the present invention.
  • these promoters may be isolated as convenient restriction digestion fragments suitable for cloning in a selected vector.
  • promoter fragments may be isolated using the polymerase chain reaction. Cloning of the amplified fragments may be facilitated by incorporating restriction sites at the 5' end of the primers.
  • the NOI or NOIs may be under the expression control of an expression regulatory element, such as a promoter and enhancer.
  • the ischaemic responsive promoter is a tissue restricted ischaemic responsive promoter.
  • tissue restricted ischaemic responsive promoter is a macrophage specific promoter restricted by repression.
  • tissue restricted ischaemic responsive promoter is an endothelium specific promoter.
  • the regulated retroviral vector of the present invention is an ILRE regulated retroviral vector.
  • the regulated retroviral vector of the present invention is an ILRE regulated lentiviral vector.
  • the regulated retroviral vector of the present invention is an autoregulated hypoxia responsive lentiviral vector.
  • the regulated retroviral vector of the present invention is regulated by glucose concentration.
  • the glucose-regulated proteins such as grp78 and grp94 are highly conserved proteins known to be induced by glucose deprivation (Attenello and Lee 1984 Science 226 187-190).
  • the g ⁇ 78 gene is expressed at low levels in most normal healthy tissues under the influence of basal level promoter elements but has at least two critical "stress inducible regulatory elements" upstream of the TATA element (Attenello 1984 ibid; Gazit et al 1995 Cancer Res 55: 1660-1663). Attachment to a truncated 632 base pair sequence of the 5 " end of the g ⁇ 78 promoter confers high inducibility to glucose deprivation on reporter genes in vitro (Gazit et al 1995 ibid).
  • this promoter sequence in retroviral vectors was capable of driving a high level expression of a reporter gene in tumour cells in murine fibrosarcomas, particularly in central relatively ischaemic/fibrotic sites (Gazit et al 1995 ibid).
  • the regulated retroviral vector of the present invention is a self-inactivating (SIN) vector.
  • SI self-inactivating
  • self-inactivating retroviral vectors have been constructed by deleting the transcriptional enhancers or the enhancers and promoter in the U3 region of the 3' LTR. After a round of vector reverse transcription and integration, these changes are copied into both the 5' and the 3' LTRs producing a transcriptionally inactive provirus (Yu et al 1986 Proc Natl Acad Sci 83: 3194-3198; Dougherty and Temin 1987 Proc Natl Acad Sci 84: 1 197-1201 ; Hawley et al 1987 Proc Natl Acad Sci 84: 2406-2410; Yee et / 1987 Proc Natl Acad Sci 91 : 9564-9568).
  • any promoter(s) internal to the LTRs in such vectors will still be transcriptionally active.
  • This strategy has been employed to eliminate effects of the enhancers and promoters in the viral LTRs on transcription from internally placed genes. Such effects include increased transcription (Jolly et al 1983 Nucleic Acids Res 1 1 : 1855-1872) or suppression of transcription (Emerman and Temin 1984 Cell 39: 449-467).
  • This strategy can also be used to eliminate downstream transcription from the 3' LTR into genomic DNA (Herman and Coffin 1987 Science 236: 845-848). This is of particular concern in human gene therapy where it is of critical importance to prevent the adventitious activation of an endogenous oncogene.
  • the regulated retroviral vector of the present invention includes but is not limited to: murine leukemia virus (MLV), human immunodeficiency virus (HIV), equine infectious anaemia virus (EIAV), feline immunodeficiency virus (FIV), caprine encephalitis-arthritis virus (CAEV), mouse mammary tumour virus (MMTV), Rous sarcoma virus (RSV), Fujinami sarcoma virus (FuSV), Moloney murine leukemia virus (Mo-MLV), FBR murine osteosarcoma virus (FBR MSV), Moloney murine sarcoma virus (Mo-MSV), ⁇ belson murine leukemia virus A-MLV).
  • MMV murine leukemia virus
  • HMV human immunodeficiency virus
  • EIAV equine infectious anaemia virus
  • FIV feline immunodeficiency virus
  • CAEV caprine encephalitis-arthritis virus
  • MMTV mouse mammary tumour
  • Retroviruses A detailed list of retroviruses may be found in Coffin et al ( Retroviruses " ' 1997 Cold Sp ⁇ ng Harbour Laboratory Press Eds JM Coffin. SM Hughes. HE Varmus pp 758-763)
  • Preferred vectors for use in accordance with the present inv ention are retroviral vectors, such as MLV vectors
  • the recombinant retroviral vectors ol the present invention are lentiviral vectors, more preferably HIV or EIAV vectors
  • the lentiviruses can be divided into primate and non-p ⁇ mate groups
  • primate lentiviruses include but are not limited to the human immunodeficiency virus (HIV), the causative agent of human auto-immunodeficiency syndrome (AIDS), and the simian immunodeficiency virus (SIV)
  • the non-p ⁇ mate lentiviral group includes the prototype 'slow virus” visna/maedi virus (VMV), as well as the related caprine arthritis- encephalitis virus (CAEV), equine infectious anaemia virus (EIAV) and the more recently described feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV)
  • lentivirus family and other types of retroviruses are unable to infect non-dividing cells such as those that make up, for example, muscle, brain, lung and liver tissue
  • Preferred vectors for use in accordance with the present invention are recombinant retroviral vectors, in particular recombinant lentiviral vectors, in particular minimal lentiviral vectors which are disclosed in WO 99/32646 and in WO98/17815 VECTOR
  • a "vector " ' denotes a tool that allows or faciliates the transfer of an entity from one environment to another.
  • some vectors used in recombinant DNA techniques allow entities, such as a segment of DNA (such as a heterologous DNA segment, such as a heterologous cDNA segment), to be transferred into a target cell.
  • the vector may then serve to maintain the heterologous DNA within the cell or may act as a unit of DNA replication.
  • vectors used in recombinant DNA techniques include plasmids. chromosomes, artificial chromosomes or viruses.
  • operably linked denotes a relationship between a regulatory region (typically a promoter element, but may include an enhancer element) and the coding region of a gene, whereby the transcription of the coding region is under the control of the regulatory region.
  • a regulatory region typically a promoter element, but may include an enhancer element
  • derivative is used in its normal sense as meaning a nucleotide sequence such as an LTR or a part thereof which need not necessarily be obtained from an vector such as a retroviral vector but instead could be derived therefrom.
  • sequence may be prepared synthetically or by use of recombinant DNA techniques.
  • virus means virus and virus-like particles that are capable of introducing a nucleic acid into a cell through a viral-like entry mechanism.
  • vector particles can, under certain circumstances, mediate the transfer of NOIs into the cells they infect.
  • a retrovirus is capable of reverse transc ⁇ bing its genetic material into DNA and inco ⁇ orating this genetic mate ⁇ al into a target cell's DNA upon transduction Such cells are designated herein as "target cells”
  • A. vector particle includes the following components a retrovirus nucleic acid, which may contain one or more NOIs, a nucleocapsid encapsidating the nucleic acid, the nucleocapsid comprising nucleocapsid protein of a retrovirus, and a membrane surrounding the nucleocapsid
  • nucleocapsid refers to at least the group specific viral core proteins (gag) and the viral polymerase (pol) of a retrovirus genome These proteins encapsidate the retrov lrus-packagable sequences and themselves are further surrounded by a membrane containing an envelope glycoprotein
  • a high titre retroviral vector is produced using a codon optimised gag and a codon optimised pol or a codon optimised env
  • codon optimised and "codon optimisation” refer to an improvement in codon usage
  • alterations to the coding sequences for viral components may improve the sequences for codon usage in the mammalian cells or other cells which are to act as the producer cells for retroviral vector particle production This is referred to as “codon optimisation”
  • codon optimisation Many retroviruses, including HIV and other lentiviruses, use a large number of rare codons and by changing these to correspond to commonly used mammalian codons, increased expression of the packaging components in mammalian producer cells can be achieved Codon usage tables are known in the art for mammalian cells, as well as for a variety of other organisms
  • a high titre lentiviral vector is produced using a codon optimised gag and a codon optimised pol or a codon optimised env
  • a high titre retroviral vector is produced using a modified and/or extended packaging signal.
  • the term "packaging signal” or “packaging sequence "” refers to sequences located within the retroviral genome which are required for insertion of the viral RNA into the viral capsid or particle.
  • the minimal packaging signal also referred to as the psi sequence
  • this minimal packaging signal encompasses bases 212 to 563 of the Mo-MLV genome (Mann et al 1983: Cell 33: 153).
  • extended packaging signal or extended packaging sequence refers to the use of sequences around the psi sequence with further extension into the gag gene. The inclusion of these additional packaging sequences may increase the efficiency of insertion of vector RNA into viral particles.
  • a high titre lentiviral vector is produced using a modified packaging signal.
  • the lentiviral construct is a based on an EIAV vector genome where all the accessory genes are removed except Rev.
  • accessory genes ' refer to a variety of virally encoded accessory proteins capable of modulating various aspects of retroviral replication and infectivity. These proteins are discussed in Coffin et al (ibid) (Chapters 6 and 7).
  • Examples of accessory proteins in lentiviral vectors include but are not limited to tat. rev, nef, vpr, vpu, vif, vpx.
  • An example of a lentiviral vector useful in the present invention is one which has all of the accessory genes removed except rev.
  • the production of lentiviral vector particles is increased by about 10 fold in the presence of EIAV Rev. ENV
  • the retroviral component includes an env nucleotide sequence
  • all or part of that sequence can be optionally replaced with all or part of another env nucleotide sequence
  • another env nucleotide sequence such as. by way of example, the amphotropic Env protein designated 4070A or the influenza haemagglutinin (HA) or the vesicular stomatitis virus G (VSV-G) protein.
  • replacement of the env gene with a heterologous env gene is an example of a technique or strategy called pseudotyping. Pseudotyping is not a new phenomenon and examples may be found in WO-A-98/05759.
  • the retroviral vector of the present invention has been pseudotyped.
  • pseudotyping can confer one or more advantages.
  • the env gene product of the HIV based vectors would restrict these vectors to infecting only cells that express a protein called CD4. But if the env gene in these vectors has been substituted with env sequences from other RNA viruses, then they may have a broader infectious spectrum (Verma and Somia 1997 Nature 389:239-242).
  • workers have pseudotyped an HIV based vector with the glycoprotein from VSV (Verma and Somia 1997 ibid).
  • the Env protein may be a modified Env protem such as a mutant or engineered Env protein. Modifications may be made or selected to introduce targeting ability or to reduce toxicity or for another pu ⁇ ose (Valsesia-Wittman et al 1996 J Virol 70: 2056-64; Nilson et al 1996 Gene Therapy 3: 280-6; Fielding et al 1998 Blood 9: 1802 and references cited therein).
  • target cell simply refers to a cell which the regulated retroviral vector of the present invention, whether native or targeted, is capable of infecting or transducing.
  • the lentiviral vector particle according to the invention will be capable of transducing cells which are slowly-dividing, and which non-lentiviruses such as MLV would not be able to efficiently transduce. Slowly-dividing cells divide once in about every three to four days including certain tumour cells. Although tumours contain rapidly dividing cells, some tumour cells especially those in the centre of the tumour, divide infrequently.
  • the target cell may be a growth-arrested cell capable of undergoing cell division such as a cell in a central portion of a tumour mass or a stem cell such as a haematopoietic stem cell or a CD34-positive cell.
  • the target cell may be a precursor of a differentiated cell such as a monocyte precursor, a CD33-positive cell, or a myeloid precursor.
  • the target cell may be a differentiated cell such as a neuron, astrocyte, glial cell, microglial cell, macrophage, monocyte, epithelial cell, endothelial cell, hepatocyte, spermatocyte, spermatid or spermatozoa.
  • a differentiated cell such as a neuron, astrocyte, glial cell, microglial cell, macrophage, monocyte, epithelial cell, endothelial cell, hepatocyte, spermatocyte, spermatid or spermatozoa.
  • Target cells may be transduced either in vitro after isolation from a human individual or may be transduced directly in vivo.
  • the present invention it is possible to manipulate the viral genome or the regulated retroviral vector nucleotide sequence, so that viral genes are replaced or supplemented with one or more NOIs which may be heterologous NOIs.
  • heterologous refers to a nucleic acid sequence or protein sequence linked to a nucleic acid or protein sequence which it is not naturally linked.
  • the term NOI i.e. nucleotide sequence of interest
  • the DNA sequence can be, for example, a synthetic DNA sequence, a recombinant DNA sequence (i.e. prepared by use of recombinant DNA techniques), a cDNA sequence or a partial genomic DNA sequence, including combinations thereof.
  • the DNA sequence need not be a coding region. If it is a coding region, it need not be an entire coding region.
  • the DNA sequence can be in a sense orientation or in an anti-sense orientation. Preferably, it is in a sense orientation.
  • the DNA is or comprises cDNA.
  • the NOI(s) may be any one or more of selection gene(s), marker gene(s) and therapeutic gene(s).
  • selection gene refers to the use of a NOI which encodes a selectable marker which may have an enzymatic activity that confers resistance to an antibiotic or drug upon the cell in which the selectable marker is expressed.
  • tk thymidine kinase
  • Particularly preferred markers are blasticidin and neomycin, optionally operably linked to a thymidine kinase coding sequence typically under the transcriptional control of a strong viral promoter such the SV40 promoter.
  • suitable NOI sequences include those that are of therapeutic and/or diagnostic application such as, but are not limited to: sequences encoding cytokines, chemokines. hormones, antibodies, engineered immunoglobulin-like molecules, a single chain antibody, fusion proteins, enzymes, immune co-stimulatory molecules, immunomodulatory molecules, anti-sense RNA. a transdominant negative mutant of a target protein, a toxin, a conditional toxin, an antigen, a tumour suppressor protein and growth factors, membrane proteins, vasoactive proteins and peptides. anti- viral proteins and ribozymes, and derivatives therof (such as with an associated reporter group).
  • coding sequences may be typically operatively linked to a suitable promoter, which may be a promoter driving expression of a ribozyme(s), or a different promoter or promoters, such as in one or more specific cell types.
  • Suitable NOIs for use in the invention in the treatment or prophylaxis of cancer include NOIs encoding proteins which: destroy the target cell (for example a ribosomal toxin), act as: tumour suppressors (such as wild-type p53); activators of anti-tumour immune mechanisms (such as cytokines, co-stimulatory molecules and immunoglobulins); inhibitors of angiogenesis; or which provide enhanced drug sensitivity (such as pro-drug activation enzymes); indirectly stimulate destruction of target cell by natural effector cells (for example, strong antigen to stimulate the immune system or convert a precursor substance to a toxic substance which destroys the target cell (for example a prodrug activating enzyme).
  • target cell for example a ribosomal toxin
  • tumour suppressors such as wild-type p53
  • activators of anti-tumour immune mechanisms such as cytokines, co-stimulatory molecules and immunoglobulins
  • inhibitors of angiogenesis or which provide enhanced drug sensitivity (such as
  • prodrugs include but are not limited to etoposide phosphate (used with alkaline phosphatase; 5-fluorocytos ' ine (with cytosine deaminase); Doxorubin-N-p- hydroxyphenoxyacetamide (with Penicillin-V-Amidase); Para-N-bis (2- chloroethyl)aminobenzoyl glutamate (with Carboxypeptidase G2); Cephalosporin nitrogen mustard carbamates (with B-lactamase); SR4233 (with p450 reductase); Ganciclov ir (with HSV thymidine kinase). mustard pro-drugs w ith nitroreductase and cyclophosphamide or ifosfamide (with cytochrome p450).
  • Suitable NOIs for use in the treatment or prevention of ischaemic heart disease include NOIs encoding plasminogen activators Suitable NOIs for the treatment or prevention of rheumatoid arthritis or cerebral malaria include genes encoding anti-inflammatory proteins, antibodies duected against tumour necrosis factor (TNF) alpha, and anti- adhesion molecules (such as antibody molecules or receptors specific for adhesion molecules)
  • the expression products encoded by the NOIs may be proteins which are secreted from the cell Alternatively the NOI expression products are not secreted and are active within the cell In either event, it is preferred for the NOI expression product to demonstrate a bystander effector or a distant bystander effect; that is the production of the expression product in one cell leading to the killing of additional, related cells, either neighbouring or distant (e g metastatic), which possess a common phenotype Encoded proteins could also destroy bystander tumour cells (for example with secreted antitumour antibody- ⁇ bosomal toxin fusion protein), indirectly stimulated destruction of bystander tumour cells (for example cytokines to stimulate the immune system or procoagulant proteins causing local vascular occlusion) or convert a precursor substance to a toxic substance which destroys bystander tumour cells (eg an enzyme which activates a prodrug to a diffusible drug) Also, the delivery of NOI(s) encoding antisense transcripts or ribozymes which interfere with
  • the NOI or NOIs of the present invention may also comprise one or more cytokine- encoding NOIs.
  • Suitable cytokines and growth factors include but are not limited to: ApoE, Apo-SAA, BDNF, Cardiotrophin-1 , EGF, ENA-78, Eotaxin. Eotaxin-2. Exodus-2, FGF-acidic. FGF-basic, fibroblast growth factor- 10 (Marshall 1998 Nature Biotechnology 16: 129).FLT3 ligand (Kimura et al (1997). Fractalkine (CX3C). GDNF. G-CSF. GM- CSF, GF- ⁇ l . insulin, IFN- ⁇ , IGF-I. IGF-II.
  • IL-1 1. IL-12, IL-13, IL-15.
  • IP-10 keratinocyte growth factor-2 (KGF-2), KGF, Leptin, LIF, Lymphotactin, Mullerian inhibitory substance, monocyte colony inhibitory factor, monocyte attractant protein (Marshall 1998 ibid), M-CSF, MDC (67 a.a.), MDC (69 a.a.), MCP-1 (MCAF), MCP-2, MCP-3, MCP-4, MDC (67 a.a.). MDC (69 a.a.), MIG, MlP-l ⁇ , MlP-l ⁇ . MIP-3 ⁇ . MIP-3 ⁇ . MIP-4, myeloid progenitor inhibitor factor-1 (MPIF-1), NAP-2, Neurturin. Nerve growth factor.
  • KGF-2 keratinocyte growth factor-2
  • KGF keratinocyte growth factor-2
  • Leptin Leptin
  • LIF Lymphotactin
  • Mullerian inhibitory substance monocyte colony inhibitory factor
  • monocyte attractant protein Marshall 1998
  • ⁇ -NGF, NT-3, NT-4, Oncostatin M PDGF-AA, PDGF-AB, PDGF-BB, PF-4, RANTES, SDFl ⁇ , SDFl ⁇ .
  • SCF SCGF, stem cell factor (SCF), TARC, TGF- ⁇ , TGF- ⁇ , TGF- ⁇ 2, TGF- ⁇ 3, tumour necrosis factor (TNF), TNF- , TNF- ⁇ , TNIL-1.
  • TPO VEGF
  • GCP-2 GRO/MGSA.
  • the NOI or NOIs may be under the expression control of an expression regulatory element, such as a promoter and/or a promoter enhancer as known as "responsive elements" in the present invention.
  • an expression regulatory element such as a promoter and/or a promoter enhancer as known as "responsive elements" in the present invention.
  • retroviral vector particles When the regulated retroviral vector particles are used to transfer NOIs into cells which they transduce, such vector particles also designated "viral delivery systems ' ' or "retroviral delivery systems".
  • Viral vectors including retroviral vectors, have been used to transfer NOIs efficiently by exploiting the viral transduction process. NOIs cloned into the retroviral genome can be delivered efficiently to cells susceptible to transduction by a retrovirus. Through other genetic manipulations, the replicative capacity of the retroviral genome can be destioyed The vectors introduce new genetic material into a cell but are unable to replicate
  • the regulated retroviral vector of the present invention can be delivered by viral or non- viral techniques
  • Non-viral delivery systems include but are not limted to DNA transfection methods
  • transfection includes a process using a non-viral vector to deliver a gene to a target mammalian cell
  • Typical transfection methods include electroporation, DNA biohstics, lipid-mediated transfection, compacted DNA-mediated transfection, liposomes, immunohposomes, pofectin, cationic agent-mediated, cationic facial amphiphiles (CFAs) (Nature Biotechnology 1996 14. 556), multivalent cations such as spermine, cationic lipids or polylysine, 1. 2, -bis oleoylo ⁇ y)-3-(t ⁇ methylammon ⁇ o) propane (DOTAP)-cholesterol complexes (Wolff and Trubetskoy 1998 Nature Biotechnology 16 421) and combinations thereof
  • Viral delivery systems include but are not limited to adenovirus vector, an adeno- associated viral (AAV) vector, a he ⁇ es viral vector, a retroviral vector, a lentiviral vector, or a baculoviral vector These viral delivery systems may be configured as a spht-intron vector A split intron vector is described in WO 99/15683
  • vectors include ex vivo delivery systems, which include but are not limited to DNA transfection methods such as electroporation. DNA biohstics, hpid- mediated transfection, compacted DNA-mediated transfection
  • the vector may be a plasmid DNA vector
  • the vector may be a recombinant viral vector
  • Suitable recombinant viral vectors include adenovirus vectors, adeno-associated viral (AAV) vectors, He ⁇ es-virus vectors, or retroviral vectors, lentiviral vectors or a combination of adenoviral and lentiviral vectors
  • AAV adeno-associated viral
  • lentiviral vectors or a combination of adenoviral and lentiviral vectors
  • gene delivery is mediated by viral infection of a target cell If the features of adenoviruses are combined with the genetic stability ot letro/lentiviruses then essentially the adenovirus can be used to transduce target cells to become transient retroviral producer cells that could stably infect neighbouring cells
  • the present invention also provides a pharmaceutical composition tor treating an individual by gene therapy, wherein the composition comprises a therapeutically effective amount of a regulated retroviral vector according to the present invention
  • the pharmaceutical composition may be for human or animal usage Typically, a physician will determine the actual dosage which will be most suitable for an individual subject and it will vary with the age, weight and response of the particular patient
  • composition may optionally comprise a pharmaceutically acceptable carrier, diluent, excipient or adjuvant
  • a pharmaceutically acceptable carrier diluent, excipient or adjuvant
  • the choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice
  • the pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable b ⁇ nder(s), lub ⁇ cant(s), suspending agent(s), coating agent(s), solubihsmg agent(s), and other carrier agents that may aid or increase the viral entry into the target site (such as for example a lipid delivery system)
  • the pharmaceutical compositions can be administered by any one or more of minipumps, inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously
  • the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccha ⁇ des to make the solution isotonic with blood
  • buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be
  • the present invention may be useful in the treatment of the disorders listed in WO-A-98/05635
  • cancer inflammation or inflammatory disease
  • dermatological disorders fever, cardiovascular effects, haemorrhage, coagulation and acute phase response
  • cachexia anorexia, acute infection. HIV infection, shock states, graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-dependent anti-thrombosis, tumour growth, invasion and spread, angiogenesis.
  • the present invention may be useful in the treatment of disorders listed in WO-A-98/07859
  • cytokine and cell proliferation/differentiation activity e g for treating immune deficiency, including infection with human immune deficiency virus, regulation of lymphocyte growth, treating cancer and many autoimmune diseases, and to prevent transplant rejection or induce tumour immunity
  • haematopoiesis e g treatment of myeloid or lymphoid diseases, promoting growth of bone, cartilage, tendon, ligament and nerve tissue, e g for healing wounds, treatment of burns, ulcers and pe ⁇ odontal disease and neurodegeneration, inhibition or activation of follicle-stimulating hormone (modulation of fertility), chemotactic/chemokinetic activity (e g for mobilising specific cell types to sites of injury or infection), haemostatic and thrombolytic activity (e g for treating hae
  • the present invention may be useful in the treatment of disorders listed in WO-A-98/09985.
  • macrophage inhibitory and/or T cell inhibitory activity and thus, anti- inflammatory activity i.e.
  • inhibitory effects against a cellular and/or humoral immune response including a response not associated with inflammation; inhibit the ability of macrophages and T cells to adhere to extracellular matrix components and fibronectin, as well as up-regulated fas receptor expression in T cells; inhibit unwanted immune reaction and inflammation including arthritis, including rheumatoid arthritis, inflammation associated with hypersensitivity, allergic reactions, asthma, systemic lupus erythematosus, collagen diseases and other autoimmune diseases, inflammation associated with atherosclerosis, arteriosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, vascular inflammatory disorders, respiratory distress syndrome or other cardiopulmonary diseases, inflammation associated with peptic ulcer, ulcerative colitis and other diseases of the gastrointestinal tract, hepatic fibrosis, liver cirrhosis or other hepatic diseases, thyroiditis or other glandular diseases, glomerulonephritis or other renal and urologic diseases, otitis or other oto-rhino-
  • retinitis or cystoid macular oedema retinitis or cystoid macular oedema, sympathetic ophthalmia, scleritis, retinitis pigmentosa, immune and inflammatory components of degenerative fondus disease, inflammatory components of ocular trauma, ocular inflammation caused by infection, proliferative vitreo-retinopathies, acute ischaemic optic neuropathy, excessive scarring, e.g. following glaucoma filtration operation, immune and/or inflammation reaction against ocular implants and other immune and inflammatory-related ophthalmic diseases, inflammation associated with autoimmune diseases or conditions or disorders here.
  • Parkinson's disease both in the central nervous system (CNS) or in any other organ, immune and/or inflammation suppression would be beneficial, Parkinson's disease, complication and/or side effects from treatment of Parkinson's disease, AIDS-related dementia complex HIV- related encephalopathy, Devic's disease.
  • Sydenham chorea Alzheimer's disease and other degenerative diseases, conditions or disorders of the CNS, inflammatory components of stokes, post-polio syndrome, immune and inflammatory components of psychiatric disorders, myelitis, encephalitis, subacute sclerosing pan-encephalitis, encephalomyelitis.
  • acute neuropathy subacute neuropathy, chronic neuropathy, Guillaim-Barre syndrome,
  • Sydenham chora myasthenia gravis, pseudo-tumour cerebri, Down's Syndrome, Huntington's disease, amyotrophic lateral sclerosis, inflammatory components of CNS compression or CNS trauma or infections of the CNS, inflammatory components of muscular atrophies and dystrophies, and immune and inflammatory related diseases, conditions or disorders of the central and peripheral nervous systems, post-traumatic inflammation, septic shock, infectious diseases, inflammatory complications or side effects of surgery, bone marrow transplantation or other transplantation complications and/or side effects, inflammatory and/or immune complications and side effects of gene therapy, e.g.
  • monocyte or leukocyte proliferative diseases e.g. leukaemia
  • monocytes or lymphocytes for the prevention and/or treatment of graft rejection in cases of transplantation of natural or artificial cells, tissue and organs such as cornea, bone marrow, organs, lenses, pacemakers, natural or artificial skin tissue.
  • Figure 1 shows an MLV-based transduction method using a Cre/LoxP system as described by Vanin et al ibid ( 1997);
  • Figure 2 shows an EIAV-based transduction method using a Cre/Lox system
  • Figure 3 shows an MLV SIN vector construct transduction method with an EIAV/HIV genome insertion using a Cre/Lox system
  • Figure 4 shows an MLV-based transduction method with HRE 3 ' LTR using a Cre/Lox P system:
  • Figure 5 shows an MLV-based transduction method for MLV SIN vector production using a Cre/Lox P system
  • Figure 6 shows an MLV-based transduction method with integration of a complete second genome construct using a Cre/LoxP system
  • Figure 7 shows the basis molecular organisation of an RNA genome and a proviral DNA genome
  • Figure 8 shows a schematic diagram of pTrap2 and pONY8z-loxP plasmids
  • Figure 9 shows an overall summary of the recombinase method
  • Figure 10a shows a FACS analysis of EV1 packaging cells prior to transduction with Trap2 vector:
  • Figure 10b shows FACS analysis of EV1 packaging cell line transduced with Trap2 at an MOI of 0.3. A 5% top slice of the highest expressers was carried out;
  • Figure 1 1 shows a validation of the method for quantitation of GFP mRNA, relative to ⁇ - actin.
  • a titration of the total RNA from EV1 clone A was used.
  • the difference in Ct values between the two assays is shown on the y axis.
  • the magnitude of the gradient must be ⁇ 0.1 for the method to be valid.
  • the gradient is 0.077. so the method is suitable;
  • Figure 12 shows the quantitation of GFP mRNA relative to control ⁇ -actin mRNA.
  • EV2 TD cells are transduced with Trap2 at an MOI of 0.3 and are the calibrator sample with the ratio designated 1.0:
  • Figure 13 shows FACS analysis of EV 1 clone A;
  • Figure 13A shows original GFP expression of the clone
  • Figure 1 B shows GFP expression 7 days after transfection with Cre recombinase (pBS 185). Excision frequency is 64%;
  • Figure 13C shows recombined clone 4 identified as being negative for GFP:
  • Figure 14 shows lacZ expression of transfected cells with and without the addition of the Cre recombinase (pBS185).
  • Figure 14 shows EV1A4 and EV2D4 clones with and without the addition of Cre recombinase (pBS185).
  • the efficiency of the insertion event was estimated to be about 12% by computer image analysis;
  • Figure 15 shows the structure of pONY8.1Z MLVHyb
  • Figure 16 shows the alignment of leader and gag regions present in vectors pONY4Z, 8Z and ATG mutated 8Z vector.
  • the latter is referred to as pONY8ZA.
  • the sequences aligned are from the Narl site in the leader to the Xbal site between the EIAV gag sequence and the CMV promoter. Sequences in the leader are shown in italic and a space is present upstream of the position of the gag ATG; and
  • Figure 17 shows a schematic representation of the structure of pONY 8.3G +/- vector genome plasmids.
  • Vanin et al describe a recombinase system whereby an initial retroviral transduction event introduces retroviral LTRs and expressed gene/s flanked by two recombinase target sites (exemplified by loxP) into a cell line.
  • Stable transduced cell lines are selected by resistance to the antibiotic neomycin and screened for high expression of the expressed gene(s) (see Figure 1 )
  • Such cell lines (Cell Line 1 ) contain retroviral insertions in integration sites that support high level expression from the retroviral genome
  • the next step involves the transfection ot the relevant recombinase expression construct (exemplified here by Cre recombinase) into the identified high expressing cell line
  • the expressed gene(s) is/are excised and a single loxP site is retained in the construct (Cell Line 2)
  • thymidine kinase gene (tk) is used as a negativ e selectible marker in combination with the drug, gancyclovir
  • the final step involv es the reinsertion of a therapeutic or marker gene of choice into the single loxP site v la a Cre- assisted mechanism
  • Cell lines are identified that have been successfully recombined (Cell Line 3) and they will produce retroviruses at the same titre as the parental Cell Line
  • FIG. 2 and Figure 3 describe the production of EIAV or HIV high titre transduced producer cell lines
  • FIG. 2 shows a minimal EIAV genome construct with the 3' U3 sequences replaced by a strong constitutive promoter, CMV A reporter gene such as blasticidin resistance gene (bsr) is flanked by loxP sites Virus is made in a transient system and is transduced into an EIAV producer cell line and clones identified that maximally express the blast marker gene A line is chosen (termed Cell Line 1) and the marker gene is excised by a Cre recombinase-assisted excision event, generating Cell Line 2
  • CMV A reporter gene such as blasticidin resistance gene (bsr) is flanked by loxP sites Virus is made in a transient system and is transduced into an EIAV producer cell line and clones identified that maximally express the blast marker gene A line is chosen (termed Cell Line 1) and the marker gene is excised by a Cre recombinase-assisted excision event, generating Cell Line 2
  • Construct B comprises two loxP sites which flank an internal expression cassette and also the native EIAV 3' LTR Therefore, this construct is recombined into the cell line such that the 5' R and U5 sequences are inherited from the packaging cell line, whereas the 3' LTR sequences are wholly derived from the recombined construct
  • the 3 ' LTR from Cell Line 2 is present downstream of the functional EIAV genome expression construct
  • This CMV-R-U5 module is still transcriptionally active but expression is directed away from the EIAV genome
  • Figure 3 shows a further aspect of the invention.
  • Construct C is based on an MLV SIN vector, w ith a deletion in the 3' U3 sequences.
  • the cassette includes an internal CMV promoter linked to EIAV R and U5 sequences.
  • a blasticidin resistance gene flanked by two loxP sites.
  • Virus is made in a transient transfection system and the genome is transduced into a packaging line.
  • Blast-resistant clones are identified and the highest expressing line is chosen for further analysis.
  • This line is transfected with Cre recombinase and the blast gene is excised.
  • the last step involves the insertion of construct B into the single loxP site.
  • a complete EIAV 3 ' LTR is introduced into the producer cell line. This leads to a CMV -driven EIAV genome expression cassette with the EIAV 3 ' LTR still located at the 3' end of the genome. Transcriptionally quiescent MLV SIN LTRs flanks these EIAV sequences.
  • FIG. 4 shows an additional aspect of the invention.
  • Construct D is an MLV-based vector with a CMV promoter in the 3' LTR in place of the U3 sequences.
  • Virus is made in a transient system and is transduced into a packaging cell line as described previously.
  • the neo and TK genes are excised by the action of Cre recombinase and construct E is recombined into the single loxP target sequence.
  • the modified MLV 3' LTR including the HRE or similarly regulated system is transferred into the packaging cell line by the recombinase mechanism. Therefore, the 5' R and U5 sequences are inherited from the producer cell line whereas the therapeutic and marker gene/s and regulated 3' LTR is inherited from construct E.
  • the final producer cell line is constitutively driven by the 5 ' CMV promoter and will produce high titre retroviral vectors which are regulated in the transduced target cells. This approach avoids the derivation of low titre transfected producer cell lines or the use of hypoxic conditions or chemical mimics for production from traditionally derived transduced producer lines.
  • FIG. 5 shows yet another aspect of the invention.
  • Construct D is an MLV-based vector with a CMV promoter in the 3' LTR as previously described. The same process is carried out as shown in Figure 4 until the final recombination is performed
  • Construct F contains a deletion in U3 sequences in the 3' LTR and an internal expression cassette comprising a promoter and gene sequences
  • the final cell line containing the Cre-mediated recombination will be CMV-d ⁇ ven and will constitutively produce high titre MLV SIN v ectors Prev iously.
  • SIN vectors have not been amenable to production by stable cell line producer technology Instead they hav e been prepared using transfection-based transient expression s stems.
  • FIG. 6 shows an MLV-based transduction method with integration of complete second genome construct by Cre/LoxP system.
  • construct 1 is called TRAP1
  • TRAP1 is an MLV v ector construct containing an internal CMV promoter operably linked to a marker gene (a truncated form of the human low affinity nerve growth factor receptor. called LNGFR).
  • the enhancer elements in the 3' U3 sequence have been excised and replaced by a 34bp loxP site.
  • Virus stocks are prepared in a transient system and the TRAP1 genome is stably transduced into packaging cell lines.
  • the modified 3 ' U3 sequences including the lox P sequence, is copied from the 3'LTR position to the 5'LTR, such that there is little 5 ' promoter activity
  • Cell lines are screened for high levels of expression of LNGFR protein by fluorescent activated cell sorter
  • Construct 2 in this example comprises a complete HIV or EIAV or also MLV retroviral genome, which is flanked by two minimal 34bp loxP recombinase sites. A strong constitutive promoter such as CMV directs transcription of the genome.
  • the complete lentivirus vector or MLV vector genome is inserted in the producer cell line. These sequences are flanked to the 5' by a small portion of MLV
  • VSAT129 and VSAT130 were synthesised which correspond to the minimal 34bp loxP sites and contain a 5' overhang for Nhel and a 3 ' overhang for Xbal.
  • the sequences 5 ' to 3 ' are as follows VSAT129 (CTAGC ATAACTTCGTATA ATGTATGCTATACGAAGTTATT) (SEQ ID No 49) and VSAT130 (CTAGAATAACTTCGTATAGC ATACATTATACGAAGTTATG (SEQ ID No 50).
  • the two oligonucleotides were treated with T4 polynucleotide kinase and were heated to 95 °C for 5 minutes, before gradual cooling to room temperature
  • the annealed and kinased oligos were hgated to a 2,830 bp Nhel/Xbal fragment from LTR plasmid (SEQ ID No 59) Fragments were hgated and correct clones of LTRloxP were identified by sequence analysis Plasmid LTRloxP was then digested with Nhel and Seal and a 2, 185bp fragment was prepared for following cloning steps
  • Plasmids TRAP1 and TRAP1G were derived from LTRloxP and the MLV genome CGCLNGFR (encodes GFP and LNGFR from an internal CMV promoter - see SEQ ID No 57) However, the GFP gene was excised by EcoRI/Bsml digestion and the 6,796bp fragment was filled in by T4 DNA polymerase and re-hgated. in order to generate plasmid CXCLNGFR.
  • Plasmid TRAP 1 was generated by ligation of a 2.185bp Nhel/Scal fragment from LTRloxP (see SEQ ID No 58) to a 4,426bp Nhel/Scal fragment from CXCLNGFR
  • Plasmid TRAP1G was generated by ligation of a 2,185bp Nhel/Scal fragment from LTRloxP to a 5,179bp Nhel/Scal fragment from CGCLNGFR.
  • the retroviral genome inserted into the loxP site in Figure 6 was based on the EIAV vector genome.
  • pONY8z (for preparation see pONYS 0Z construction below).
  • pONYSz was cut with SnaBI and Nrul, and the 4358bp fragment punfied and self-ligated to form pONY8z-shuttle
  • This plasmid has unique 5' sites (Dralll and Bglll) and unique 3' sites (PvuII and BspLUII)
  • Oligonucleotides encoding the 34bp loxP sites were inserted with suitable base pair overhangs at the unique 5' Dralll site and then the unique 3' BspLUII.
  • Plasmid pONY8z-loxP was made as follows Plasmid pONY-8z-shuttleloxP was digested with BsrG I and NspV, and the 3670bp fragment was purified as the vector fragment The insert for ligation to this fragment was de ⁇ ved from pONYSz by partial digestion with BsrGl (two sites) followed by digestion with NspV A 7.328bp fragment was punfied and hgated to the 3670bp fragment described above
  • Cie lecombinase plasmid as used in this system is pBS 185 (Gibco)
  • pTrap2 MLV self-inactivating (SIN) vector
  • SIN MLV self-inactivating
  • the vector transcribes the marker gene GFP from an internal CMV promoter Trap2 vector was used to transduce EIAV packaging cell lines EVl and EV2
  • the EV cell lines are based on human TE671 cells and express EIAV gag/pol proteins and VSV-G envelope, regulated by a temperature-sensitive switch High expressing clones of transduced EVl and EV2 cells were identified by FACS analysis for GFP Individual clones expressing high levels of GFP were then selected
  • the GFP expression cassette was excised following transient transfection with a Cre recombinase expression plasmid
  • the derived cell line, EV-loxP contains a single loxP site and minimal sequences derived from the MLV construct pTrap2
  • An EIAV genome was engineered to contain loxP sites flank
  • This genome construct and Cre recombinase were co-transfected into EV-loxP Stable cell lines expressing lacZ were selected by FACS and cell lines were cloned by limiting dilution Therefore, we have introduced an entire EIAV genome expression cassette into a single loxP site This site was previously identified by MLV transduction as highly permissive for transgene expression A 5' CMV promoter transcribes the lentiviral genome in the producer cell line but the expression site was originally identified by MLV transduction This method is adaptable to the generation of transduced producer cell lines for other lentiviral vector systems Materials and Methods
  • Plasmid pTrap2 was made as follows: A plasmid containing a single MLV LTR plasmid (LTRplasmid - SEQ ID No 59) was digested with Nhel and Xbal and a 34 bp minimal loxP site was introduced with relevant sticky ends. This insertion step removes the MLV U3 enhancer elements which lie within the excised Nhel- Xbal fragment. The LTR-loxP plasmid was linearised by digestion with Nhel and was ligated to a 6.8kb Nhel fragment from the MLV construct CZCG (See SEQ ID No 55). This construct expresses lacZ from the 5' U3 promoter and GFP from an internal CMV promoter. The resulting pTrap2 construct is shown in Figure 8.
  • the EIAV genome construct pONY ⁇ .OZ and pONY8.1Z were prepared as follows:
  • pONY8.0Z was derived from pONY4.0Z (see WO 99/32646) by introducing mutations which 1) prevented expression of TAT by an 83nt deletion in the exon 2 of tat ) prevented S2 ORF expression by a 51nt deletion 3) prevented REV expression by deletion of a single base within exon 1 of rev and 4) prevented expression of the N-terminal portion of gag by insertion of T in ATG start codons, thereby changing the sequence to ATTG from ATG.
  • the wild type EIAV sequence Ace No. U01866 these correspond to deletion of nt 5234-5316 inclusive, nt 5346-5396 inclusive and nt 5538. The insertion of T residues was after nt 526 and 543.
  • pONY ⁇ . lZ was obtained directly from pONY8.0Z by digestion with Sail and partial digestion with Sapl. Following restriction the overhanging termini of the DNA were made blunt ended by treatment with T4 DNA polymerase. The resulting DNA was then religated. This manipulation results in a deletion of sequence between the LacZ reporter gene and just upstream of the 3 'PPT. The 3' border of the deletion is nt 7895 with respect to wild type EIAV, Ace. No. U01866. Thus pONY8.1Z does not contain sequences corresponding to the EIAV RREs.
  • Plasmid pONYSz was linearised by Bglll, and a single loxP site was cloned into Bglll, immediately upstream of the 5 ' CMV promoter, to produce pONY8z-loxP. Plasmids pONY3.2iresHYG and pHCMV-VSVG were used in the derivation of cell lines EVl and EV2. The plasmid pONY3.2iresHYG was constructed as follows:
  • pONY3.IREShyg was derived from pONY3.2.
  • pONY3.2 is a derivative of pONY3.1 in which expression of TAT and S2 are ablated by an 83nt deletion in the exon 2 of tat a 5 lnt deletion in S2 ORF.
  • the wild type EIAV sequence Ace No. U01866 these correspond to deletion of nt 5234-5316 inclusive and nt 5346-5396 inclusive.
  • This fragment was introduced into the expression vector pHORSE IRES hyg which was made as follows.
  • pHORSE (see WO 99/32646) was cut with SnaBI and Notl which excises a fragment running from the CMV promoter through EIAV gag/pol and introduced into pIRESlhyg (Clontech) digested with the same enzymes. This plasmid was then cut with Sse8387I and BstEII and then ligated with the Sse8387I to BstEII fragment from pONY3.2. The sequence of the plasmid is set out in SEQ ID No 51.
  • Transient MLV vector preparations pseudotyped with RD114 cat endogenous envelope were made as described previously (Soneoka et al., 1995).
  • EIAV vector was harvested from confluent monolayers following 3 days induction of VSV-G expression at 32°C.
  • MLV vector preparations were titred in triplicate on HT1080 fibrosarcoma cells.
  • EIAV vector preparations were titred by GFP and lacZ on D17 dog osteosarcoma cells.
  • Figure 8 shows a schematic diagram of pTrap2 and pONY8z-loxP, plasmids used in this study.
  • Trap2 MLV vector was made in a transient system with the amphotropic 4070.A envelope. It gave a GFP titre of 1.7xl0 6 T.U. per ml. Trap2 vector however also gave a lacZ titre of 9.4x10 D T.U. per ml. This shows that replacement of the Nhel-Xbal fragment from the MLV U3 region with loxP does not completely inactivate the MLV U3 promoter. Therefore Trap2, as constructed, is a partial SIN vector.
  • EVl and EV2 cells were transduced with Trap2 vector at a multiplicity of infection (MOI) of 0.3. This was done to insert single copies of the MLV genome into the packaging lines.
  • MOI multiplicity of infection
  • Transduced EVl and EV2 cells were analysed by FACS (see Figure 10) and the top 5% of GFP expressing cells were sorted and expanded. Clonal lines were derived by limiting dilution and four clones of EVl and EV2 were chosen by visual inspection.
  • a quantitative TaqMan RT-PCR reaction was established in order to identify which of the four clones of EVl and EV2 were the highest expressors of GFP mRNA.
  • Total RNA was analysed by RT-PCR for GFP and ⁇ -actin. Quantitation was calculated by direct comparison of the Ct values (Cycle threshold). This was possible as it was proved that the two individual RT-PCR reactions are of similar efficiency (see Figure 1 1).
  • Figure 5 shows the n-fold difference in GFP : ⁇ -actin ratio for clones EVl A to D and EV2 A to D. All ratios are defined relative to a calibrator sample, defined as a ratio of 1.0. The calibrator sample used was RNA from EV2 cells transduced with Trap2 at an MOI of 0.3.
  • the process of retroviral integration copies the loxP-containing modified 3 " U3 to the 5' position. Therefore, one can excise the majority of the MLV Trap2 integration by the action of Cre recombinase. This will leave a single modified LTR, suitable for lentiviral genome integration.
  • EVl clone A and EV2 clone D were transfected by the Cre expression plasmid pBS185
  • Recombined clones were identified by limit dilute cloning cells and checking by microscope and FACS for loss of GFP expression.
  • FIG. 14 shows lacZ expression of transfected cells withand without the addition of Cre recombinase (pBS185)
  • the efficiency of the insertion event was estmated to be -12% by computer image analysis
  • the EIAV vector configurations described previously utilise a single promoter - 0 transgene cassette located internally in the vector
  • the promoter-transgene cassette is CMV-LacZ
  • a gene from the 5 ' LTR promoter for example a marker gene such as green fluorescent protein (GFP), a resistance marker such as neomycin phosphotransferase (neo) or another protein or a biologically active 5 entity such as a ribozyme
  • GFP green fluorescent protein
  • a biologically active 5 entity such as a ribozyme
  • the MLV U3 region was introduced into pONYSZ vector by replacement of the 3 ' LTR with a synthetic MLV/EIAV LTR made by the overlapping PCR technique, using the following primers and templates
  • the EIAV PPT/U3 sequence was amplified from pONY ⁇ 1Z using primers
  • the MLV U3 region was amplified from pHITl 1 1 (Soneoka et al , (1995) Nucleic Acids Res 23, 628-633) using KM004 CTGTGGGGTTTTTATGAGGGGTTTTATAATGAAAGACCCCACCTGTAGGTTTG
  • the MLV U3/EIAV R/U5 was amplified from pONY ⁇ .1 Z using primers
  • KM002 GAGCGCAGCGAGTCAGTGAGCGAG (SEQ ID No 7)
  • AGAGCCCACAACCCCTCACTCGGGGGGCACTCAGATTCTGCGGTCTGAGTCC CTTC SEQ ID No 8.
  • the PCR products described above were purified and then used as templates in new PCR reactions to link them together to obtain a 992bp product.
  • the final product contains two Sapl sites which flank the hybrid LTR. These allow introduction of the PCR product into the corresponding Sapl sites present in the pONYSZ or pONYS. lZ v ector plasmid, thereby creating pONY ⁇ Z MLVHyb and pONY8.1 MLVHyb.
  • the sequence of the hybrid LTR in these plasmids was confirmed by sequencing.
  • the titres obtained from the vectos in transient transfection assays are shown in Table 1. The titres were very similar to the titres from the parental construct pONY ⁇ Z and pONYS.lZ indicating that replacement of the EIAV U3 region with that of MLV had little or no detrimental effect on the infectious cycle of the vectors.
  • Titre was measured on D17 cells and is expressed as LacZ forming units/ml (l.f.u./ml). Transfections were carried out in 293T cells using the vector plasmid shown and pRV67 (VSV-G expression plasmid), and pONY3.1 (EIAV gag/pol expression plasmid).
  • the EIAV promoter was also replaced by the human cytomegalovirus (CMV) promoter using a similar strategy.
  • CMV human cytomegalovirus
  • the primers and templates were the same except that KM003 was replaced by KM008: GGCCATCGTGCCTCCCCACTCCTGCAGTTATAAAACCCCTCATAAAAACCCCA
  • KM004 was replaced by KM009:
  • KM005 was replaced by KM010:
  • KM006 was replaced by KM011 :
  • the template for the PCR reaction with primers KM009 and KM010 was pONY2.1LacZ. 0 This plasmid contains a single CMV promoter.
  • the combined PCR product of 1319 bp was digested with Sapl and introduced into the pONY8Z or pONY8.1Z backbone as described above for pONY8Z MLVHyb.
  • R2 CAATATTTCGCTCTTAGGAGCTGGAATGATGCCTTTCCAATCTACTACAAT TATTAATCTGGAGGCCCAATCTTTACAGCAGAAATTGCCCACCAATG (SEQ ID No 18);
  • pONY8Z MLVHyb and pONY8Z CMVHyb which had been prepared for ligation by digestion with the same enzymes. These plasmids were designated pONY8ZA or pONYSZA MLVHyb and pONY ⁇ ZA CMVHyb.
  • the sequence for pONY ⁇ ZA CMVHyb is provided in SEQ ID No.
  • GFP GFP
  • pEGFP- 1 Clontech
  • T4 DNA polymerase T4 DNA polymerase
  • This fragment was then Hgated into pONY ⁇ ZA or pONY ⁇ ZA MLVHyb and pONY ⁇ ZA CMVHyb prepared for ligation by digestion with Xbal and subsequent filling in with T4DNA polymerase.
  • the resulting vector plasmids were called pONYSGZA or pONYSGZA MLVHyb and pONYSGZA CMVHyb.
  • Other genes can be inserted at this site by manipulations apparent to those skilled in the art.
  • the proposed scheme was evaluated using a derivative of pONYSGZA CMVHyb in which a loxP site was introduced into the Pstl site between the EIAV sequences (required for efficient integration) and the CMV promoter in the 3'LTR. After transduction the integrated vector will thus have a loxP-CMV cassette located in the 5 ' LTR and 3 'LTR's and therefore full length transcripts of the vector genome will be driven by the CMV promoter, which is a powerful promoter.
  • pONY8GZA CMVHyb contains many Pstl sites hence it was modified to allow insertion of the loxP site by digestion with Xbal and Nhel and religation to create the subclone, pONY CMVHyb.
  • This plasmid has a unique Pstl site in the hybrid LTR.
  • the loxP site was inserted into this site using two complimentary oligonucleotides which when annealed formed Pstl-compatible termini. These were termed loxP POS PSTI [GATAAC TTCGTATAATGTATGCTATACGAAGTTATCTGCA] (SEQ ID No
  • pONY CMVHyb loxP The sequence and orientation of the loxP site was confirmed by DNA sequencing and the plasmid called pONY CMVHyb loxP.
  • the central part of the vector genome was then reintroduced into this subclone by transfer of the Notl-BstEII fragment from pONY ⁇ GZA CMVHyb into pONY CMVHyb cut the same way.
  • the resulting vector was termed pONYSGZA CMVHyb loxP.
  • the plasmid can be introduced into a packaging cell line by transfection or vector particles can be made using the 293T and these used to transduce the packaging cell line. Since the vector is derived from EIAV, rather than MLV, it is able to transduce non-dividing cells or slowly dividing cells. In this situation it has been hypothesised that integrations occur at chromosomal sites that are constitutively open; that is, are likely to be sites at which high levels of transcription will be maintained for extended periods. This may be important for the long term usefulness of the producer cell line and thus represents an advantage of strategy using transduction.
  • Producer cell lines were made by transfection or transduction of a TE671 -derived cell line (EVl IE) which has stably integrated copies of VSV-G and the synthetic EIAV gag/pol under the control of CMV promoters.
  • EVl IE TE671 -derived cell line
  • the cell line which expressed the highest level of RNA was then tested for production of transducing vector particles 5 days after changing the temperature of incubation from 37C to 32°C At 32°C VSV-G expression is induced however maximal levels ot VSV-G are only obtained after 5 days at the permissive temperature (see WO 00/52188)
  • the cell line producing the highest titre, EVl IE CMV loxP was selected tor further work
  • EVl lEloxP cells were transfected with cre recombinase expression plasmid, pBS185 (Gibco), which results in excision of the EIAV vector between the lo ⁇ P sites This leaves a loxP-CMV promoter R-U5 sequence in the cells
  • Cells from which the EIAV vector genome had been excised were selected on the basis of low levels of GFP expression by FACS and assumed to be clonal on the basis of the clonahty of EVl IE CMV loxP These were termed EVl lEloxP ⁇ and used as targets for new EIAV vector genomes
  • Titre was measured on D17 cells and is expressed as LacZ forming units/ml (l.f.u./ml). Transfections were carried out in 293T cells using the vector plasmid and gag/pol expression plasmid shown and pRV67 (VSV-G expression plasmid) (See WO 00/52188).
  • REV+ and REV- reflect the rev expression status of the vectors.
  • REV+ reflects vectors which express the REV protein.
  • REV- reflects expression vectors which do not express the REV protein.
  • the gag/pol expression plasmid shown in Figure called called called pESYNGP was constructed as follows: The codon-optimised EIAV gag/pol ORF was synthesised by Operon Technologies Inc., Alameda and supplied in a proprietary plasmid backbone, GeneOp. The complete fragment synthesised included sequences flanking the EIAV gag/pol ORF: tctagaGAATTCGCCACCATG- EIAV gag/pol- UGAACCCGGGgcggccgc (SEQ ID No 44). The ATG start and UGA stop codons are shown in bold. Xbal and Notl sites are in lower case. These were used to transfer the gag/pol ORF from GeneOp into pCIneo (Promega) using the Nhel and Notl sites in the latter.
  • pESDSYNGP An alternative expression plasmid for expression of the synthetic EIAV gag/pol could also be used. It is called pESDSYNGP and its construction is described as follows:
  • ESDSYNGP was made from pESYNGP by exchange of the 306bp EcoRI-Nhel fragment, from just upstream of the start codon for gag/pol to approximately 300 base pairs inside the gag/pol ORF with a 308bp EcoRI-Nhel fragment derived by digestion ot a PCR made using pESYNGP as template and using the following primers SD FOR
  • Packaging/Producer cells may be engineered by physically linking the genome and EIAV REV expression cassettes In this way stable transfectants may be generated which contain the vector genome and the EIAV REV expression cassette in the same chromatin environment This manipulation may ensure that the relative levels of transcription of the vector genome and the REV expression cassette are maintained leading to an increased duration of vector production from the producer cells
  • EIAV vector genomes plasmids in which there is a downstream expression cassette for synthetic EIAV REV protein
  • the promoters tested were FB29. PGK, TK, CMV, SV40 and RSV
  • the loxP sites were engineered into the vector plasmid backbone in such a way that the genome and introduced promoter-REV expression plasmid was flanked
  • the complete vector-REV cassette can be recombined into loxP sites in the target cell
  • the complete construction of the FB29 and PGK containing plasmids is described here.
  • the REV expression construct was inserted in the both orientations with respect to the
  • Plasmids in which the FB29 or PGK promoters drive REV expression are being utilised for construction of stable producer cell lines.
  • an Sfil site was inserted downstream of the EIAV vector sequence. This site is the insertion site for the promoter REV cassettes.
  • the construction was made as follows. pONY ⁇ Z was digested with Ehel and Nrul, the ends were blunted by treatment with T4 DNA polymerase and religated. The resulting plasmid, pONY ⁇ Z delta, is thus deleted with respect to the leader, gag, reporter cassette and most of the Rev/RRE regions.
  • pONY8Z delta was mutated to contain loxP sites inserted in the Drall site immediately to the 5 ' of the CMV promoter and in the BspLUl II site to the 3 ' of the vector genome.
  • the loxP sites were inserted using complementary nucleotide pairs which when annealed had overhanging termini suitable for cloning into these sites and were inserted in two steps of cloning.
  • the oligonucleotides for insertion into the Dralll site were
  • VSAT 158 [GTGATAACTTCGTATAATGTATGCTATACGAAGTTATCACTAC] (SEQ ID No 23)
  • VSAT 155 [GTGATAACTTCGTATAGCATACATTATACGAAGTTATCACGTA] (SEQ ID No 24)
  • VSAT 156 [CATGTATAACTTCGTATAATGTATGCTATACGAAGTTATA] (SEQ ID No 25) and VSAT 157 [CATGTATAACTTCGTATAGCATACATTATACGAAGTTATA] (SEQ ID NO: 25)
  • Plasmids were selected in which the orientation of the loxP at both sites were the same and the same as the EIAV vector genome.
  • the modified plasmid was called pONY8Z delta 2xloxP.
  • pONYSZ delta 2xloxP has a unique PvuII site downstream of the deleted EIAV vector genome into which annealed complementary oligonucleotides encoding Sfil sites were inserted.
  • the oligonucleotides were:
  • Clones which had the Sfil - Srfl sites in either orientation were selected for further work. These were called pONY8Z delta Sfil FOR and REV.
  • the FB29 promoter was amplified from pRDF (Cosset FL, et al.J Virol 1995 Dec;69(12):7430-6) using primers:
  • the PGK promoter was amplified from pPE327 using primers
  • PGK NEG [CGTCATGCTAGCCTGGGGAGAGAGGTCGGTG] (SEQ ID No 32)
  • the PGK promoter sequence obtained from this plasmid was the same as the sequence of
  • Ml 1958 is changed from G to A.
  • the TK promoter and intron was amplifed from pRL-
  • the RSV promoter was amplifed from pREP7 (Invitrogen) with
  • the SV40 promoter was amplifed from pCIneo (Promega) with:
  • PCR fragments were digested with Bglll and Nhel and Hgated into pSLl 180 (Pharmacia) which had been prepared by digestion using the same enzymes. Following transformation into E.coli DNA was prepared and the sequence of the promoters checked by DNA sequencing. Clones in which the correct promoter sequence was present were used for further work and were called pSL1180-FB29, pSLl l ⁇ O-PGK, pSL1 180-RSV, pSL1 180-SV40, pSL1 180-TK.
  • pE syn REV is a pCIneo based plasmid (Promega) which was made by introducing the EcoRI to Sail fragment from the synthetic EIAV REV plasmid into the polylinker region of the plasmid using the same sites.
  • the synthetic EIAV REV plasmid made by Operon contains a codon-optimised EIAV REV open reading frame flanked by EcoRI and Sail. The sequence of this fragment is shown as
  • oligonucleotides used for this were as follows:
  • Clones in which the Sfil was located 5' of the Bglll site were selected were used for further work.
  • the plasmid obtained after this two step manipulation was termed pE syn REV delta 2xSfiI. It has the following features: 5'SfiI sites - Bglll site - CMV promoter and intron - Nhel site - E syn REV - polyA site - 3 'Sfil site.
  • the CMV promoter can be excised by digestion with Bglll and Nhel and replaced with the promoter of choice obtained from the pSL1 180 series of clones by digestion with the same enzymes. Construction details are included from this point for only the constructs which contained FB29 and PGK promoters, however a similar scheme was used for the other promoters, except that a partial Sfil digestion was required for transfer of the SV40-REV cassette.
  • Promoter fragment were obtained from pSL1 180 - FB29 and pSL1 180 - PGK by digestion with Bglll and Nhel and Hgated into pE syn REV delta 2xSfiI digested with the same enzymes
  • the resulting plasmids were called FB29 E SYN REV and PGK E SYN
  • pONYS 1G SIN MIN and pONY4G were obtained by digestion with Sgfl (which has unique site in the CMV promoter driving the EIAV vector genome) and Muni (which cuts in the 3'LTR) and hgated in to pONYSZ delta Sfil FOR and REV prepared for ligation by digestion with the same enzymes
  • Sgfl which has unique site in the CMV promoter driving the EIAV vector genome
  • Muni which cuts in the 3'LTR
  • promoter-REV cassettes were moved from FB29 E SYN REV and PGK E SYN REV into pONY8G Sfil FOR and REV, pONY8 1G SIN MIN Sfil FOR and REV and pONY4G Sfil FOR This manipulation was achieved as follows FB29 E syn REV. PGK E syn REV.
  • Titres obtained from a representative experiment in which the vector-REV constructs were tested by transient 293T production assay.
  • the vector constructs were cotransfected with pE synGP, the synthetic EIAV gag/pol expression plasmid, and pRV67, VSV-G expression plasmid. Titres were measured in D17 cells.
  • Titre was assessed on D 17 cells and is expressed as green fluorescent protein cell units/ml (g.f.u./ml). Transfections were carried out with pE syn GP KOZAK and pRV67 as described previously. * pONYSG Sfil FOR is identical to the pONY8.3 derivatives except that there is no promoter-REV expression cassette is inserted in the Sfil site
  • pONYSG is a standard EIAV vector genome used for comparative purposes
  • pONY8.3G PGK + is shown as SEQ ID No 48.
  • the present invention provides high titer regulated retroviral vectors.
  • These regulated retroviral vectors include lentivectors.
  • HRE-regulated vectors and functional SIN vectors which can be produced at high titres from derived producer cell lines.
  • the present invention also provides a method other than retroviral transduction for the transfer of a regulated retroviral vector into a derived producer cell line.
  • This method comprises a recombinase assisted method which allows for the production of high titer regulated retroviral vectors.
  • the present invention relates to the selection of cells which express high levels of a retroviral vector genome and exchange of this retroviral genome for the vector genome of choice, preferably a regulated retroviral vector genome or a lentiviral vector genome using a cre/loxP recombination system.
  • the present invention enables regulated retroviral vectors to be produced at high titres from transduced producer cell lines.
  • the present invention relates to the selection of cells which express high levels of a retroviral vector genome and exchange of this retroviral genome for the vector genome of choice, preferably a regulated retroviral vector genome or a lentiviral vector genome using a cre/loxP recombination system and a retroviral vector producton system which incorporates a REV protein production system.
  • the present invention enables regulated retroviral vectors to be produced at high titres from transduced producer cell lines.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP00964529A 1999-10-05 2000-10-05 Zellen, die retrovirale vektoren produzieren Withdrawn EP1218528A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9923558.2A GB9923558D0 (en) 1999-10-05 1999-10-05 Producer cell
GB9923558 1999-10-05
PCT/GB2000/003837 WO2001025466A1 (en) 1999-10-05 2000-10-05 Producer cell for the production of retroviral vectors

Publications (1)

Publication Number Publication Date
EP1218528A1 true EP1218528A1 (de) 2002-07-03

Family

ID=10862172

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00964529A Withdrawn EP1218528A1 (de) 1999-10-05 2000-10-05 Zellen, die retrovirale vektoren produzieren

Country Status (5)

Country Link
EP (1) EP1218528A1 (de)
JP (1) JP2003511039A (de)
AU (1) AU7545500A (de)
GB (2) GB9923558D0 (de)
WO (1) WO2001025466A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143557A (en) 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US7351578B2 (en) 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
EP1173460B1 (de) 1999-03-02 2009-09-16 Life Technologies Corporation Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
NZ539430A (en) 1999-12-10 2006-09-29 Invitrogen Corp Use of multiple recombination sites with unique specificity in recombinational cloning
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
US9738907B2 (en) * 2002-02-01 2017-08-22 Oxford Biomedica (Uk) Limited Viral vector
WO2005054438A2 (en) 2003-12-01 2005-06-16 Invitrogen Corporation Nucleic acid molecules containing recombination sites and methods of using the same
EP1652932A1 (de) * 2004-11-02 2006-05-03 GBF Gesellschaft für Biotechnologische Forschung mbH Verfahren zur Erzeugung von Zelllinien die Virus produzieren und Zelllinien
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
EP1919497B1 (de) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Lichtaktivierter kationenkanal und dessen verwendung
WO2008086470A1 (en) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8401609B2 (en) 2007-02-14 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
JP5801188B2 (ja) 2008-04-23 2015-10-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 標的細胞を光刺激するためのシステム、方法、および組成物
MY152003A (en) 2008-05-29 2014-08-15 Univ Leland Stanford Junior Cell line, system and method for optical control of secondary messengers
CA2728238C (en) 2008-06-17 2019-03-12 M. Bret Schneider Methods, systems and devices for optical stimulation of target cells using an optical transmission element
MY162929A (en) 2008-06-17 2017-07-31 Univ Leland Stanford Junior Apparatus and methods for controlling cellular development
US9101759B2 (en) 2008-07-08 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
EP2547762B1 (de) 2010-03-17 2018-04-25 The Board of Trustees of the Leland Stanford Junior University Lichtempfindliche ionendurchgangsmoleküle
CA2816968C (en) 2010-11-05 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Optically-controlled cns dysfunction
CA2816972C (en) 2010-11-05 2019-12-03 The Board Of Trustees Of The Leland Stanford Junior University Control and characterization of memory function
WO2012061679A2 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
EP2635111B1 (de) 2010-11-05 2018-05-23 The Board of Trustees of the Leland Stanford Junior University Stabilisierte opsin-proteine mit stufenfunktion und verwendungsverfahren dafür
WO2012061688A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of reward-related behaviors
US9522288B2 (en) 2010-11-05 2016-12-20 The Board Of Trustees Of The Leland Stanford Junior University Upconversion of light for use in optogenetic methods
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
WO2012099540A1 (en) * 2011-01-17 2012-07-26 Agency For Science, Technology And Research Cmv promoter variants
ES2724803T3 (es) 2011-12-16 2019-09-16 Univ Leland Stanford Junior Polipéptidos opsinas y métodos de utilización de los mismos
CN104363961B (zh) 2012-02-21 2017-10-03 斯坦福大学托管董事会 用于治疗盆底神经源性病症的组合物和方法
JP6594854B2 (ja) 2013-03-15 2019-10-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 行動状態の光遺伝学的制御方法
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
JP6549559B2 (ja) 2013-04-29 2019-07-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 標的細胞における活動電位の光遺伝学的調節のための装置、システム及び方法
JP6621747B2 (ja) 2013-08-14 2019-12-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 疼痛を制御するための組成物及び方法
WO2016209654A1 (en) 2015-06-22 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0125466A1 *

Also Published As

Publication number Publication date
GB0206055D0 (en) 2002-04-24
WO2001025466A1 (en) 2001-04-12
AU7545500A (en) 2001-05-10
GB2369121A (en) 2002-05-22
GB9923558D0 (en) 1999-12-08
JP2003511039A (ja) 2003-03-25

Similar Documents

Publication Publication Date Title
WO2001025466A1 (en) Producer cell for the production of retroviral vectors
EP2194137B1 (de) Zellen beinhaltend Kodon-optimierte lentivirale Partikel
EP1895010B1 (de) Auf dem Virus der infektiösen Pferdeanämie (EIAV) basierende Vektoren
EP1504108B1 (de) Lentiviraler Vektor
EP1017837B1 (de) Retrovirale vektoren, die funktionelle spleiss-donor- und spleiss-akzeptor-stellen enthalten
US6969598B2 (en) Methods for producing high titre vectors and compositions used in such methods
WO1999015684A9 (en) Expression of genes in hematopoietic stem cells in hischaemic conditions
US9738907B2 (en) Viral vector
WO2000056910A1 (en) Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
US20030143205A1 (en) Alphavirus expression systems
AU2001248619C1 (en) Method
GB2356200A (en) Hybrid viral vectors
AU2001248619A1 (en) Method
CA2343324A1 (en) Polynucleotide constructs and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020415

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020415;LT PAYMENT 20020415;LV PAYMENT 20020415;MK PAYMENT 20020415;RO PAYMENT 20020415;SI PAYMENT 20020415

17Q First examination report despatched

Effective date: 20041027

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050308